Authored with input from current guidelines: American Society of Colon and Rectal Surgeons (ASCRS) 2022, European Association of Endoscopic Surgery (EAES)/European Society of Gastrointestinal Endoscopy (ESGE) 2020, National Institute for Health and Care Excellence (NICE) NG143 (2019, reaffirmed 2022), and supported by key systematic reviews and meta-analyses (Cochrane Database Syst Rev 2023; PMID: 36758712; Lancet Gastroenterol Hepatol 2021; PMID: 33444275).
Epidemiology and Pathophysiology
Hemorrhoidal disease affects approximately 4.4% of the general population annually, with up to 50% of adults over age 50 reporting symptoms (ASCRS Clinical Guidelines, 2022). Hemorrhoids are vascular cushions—composed of arteriovenous connections, connective tissue, and smooth muscle (the submucosal hemorrhoidal plexus)—located at the 3, 7, and 11 o’clock positions in the_ANAL_ canal. They become pathologic when they prolapse, hypertrophy, or thrombose due to increased intra-abdominal pressure (e.g., chronic straining, pregnancy, obesity), prolonged sitting, portal hypertension, or connective tissue disorders.
Crucially, internal hemorrhoids (above the dentate line) are innervated viscerally and typically cause painless bleeding or prolapse; external hemorrhoids (below the dentate line) are somatically innervated and can cause severe pain—especially when thrombosed.
Differential Diagnosis: Why Accurate Diagnosis Is Critical
Misattribution of anorectal symptoms to hemorrhoids is common (~30% of primary care referrals; Br J Surg 2020), potentially delaying diagnosis of life-threatening conditions. Key differentials include:
| Condition | Key Distinguishing Features |
|---|---|
| Anal fissure | Sharp, tearing pain during defecation; sentinel pile; linear ulcer in posterior midline (85–90% of cases). |
| Proctitis/IBD | Mucopurulent discharge, tenesmus, diarrhea; endoscopic/histologic evidence of inflammation. |
| Anorectal varices | Associated with portal hypertension; bleed from superior rectal (not inferior) vessels; often massive, life-threatening hematochezia. Endoscopic finding: blue-tinted submucosal collaterals above dentate line. Management differs profoundly—banding is contraindicated due to high perforation risk. |
| Anal cancer / squamous cell carcinoma | Persistent ulcer, induration, fistula, or mass; risk factors include HPV, smoking, immunosuppression. Biopsy required. |
| Pelvic floor dysfunction / anismus | Chronic straining, sensation of obstruction without organic pathology; defecography may show non-relaxing puborectalis. |
🔑 Clinical Pearl: All patients >45 years with new-onset rectal bleeding—or <45 with alarm features (anemia, weight loss, family history of CRC)—require structural evaluation (colonoscopy or FIT-DNA testing + colonoscopy if positive) before attributing symptoms to hemorrhoids. (NICE NG143; USPSTF B recommendation)
Diagnostic Evaluation: A Stepwise Approach
1. History
- Bleeding: Hemorrhoidal bleeding is typically intermittent, bright red, post-defecatory, non-mixed with stool, and seen on toilet paper or in the bowl. Persistent, painless hematochezia warrants colonoscopy to exclude colonic neoplasia.
- Prolapse: Graded using the Hollander–Wangenheim–Rippe system:
- Grade I: Bleeds but does not prolapse
- Grade II: Prolapses during defecation and spontaneously reduces
- Grade III: Prolapses and requires manual reduction
- Grade IV: Chronically prolapsed, irreducible (may be strangulated)
- Thrombosed external hemorrhoid: Onset of severe perianal pain over 12–48 hours; exam reveals a tense, tender, violaceous submucosal nodule (≤1–3 cm) at the anal verge. Pain typically peaks at 72 hours and gradually subsides over 7–10 days as inflammation resolves.
2. Physical Examination
- Inspection: Look for external thrombosis, skin tags, anal fissures, fistula openings, or mass lesions.
- Digital Rectal Exam (DRE): Essential to rule out strictures, masses, or fecal impaction. Not contraindicated in acute hemorrhoids, though may be uncomfortable.
3. Anoscopy
- First-line procedural diagnostic tool for internal hemorrhoids. Allows visualization of mucosa above dentate line; detects internal prolapse and avoids misdiagnosing rectal prolapse.
- Perform without distension to minimize discomfort and bleeding risk.
⚠️ Red Flags Requiring Further Workup:
- Age <45 with painful hematochezia (think fissure, IBD)
- Painless hematochezia + age >45 → colonoscopy
- Persistent symptoms despite 2–4 weeks of conservative therapy
- Unexplained iron-deficiency anemia
Management: Evidence-Based Algorithm
I. First-Line Conservative Management (All Grades)
A. Lifestyle and Behavioral Modifications
- Fiber intake: 25–35 g/day (10–14 g/day increase over baseline) from whole grains, vegetables, psyllium (e.g., Metamucil®). Strong recommendation—meta-analysis shows >60% symptom improvement vs placebo (Cochrane 2023).
- Hydration: ≥1.5–2 L/day to soften stool; evidence strongest when combined with fiber.
- Toilet habits: ≤2 min on toilet, no straining. Prolonged sitting increases venous pressure (mean anorectal pressure ↑ 60 mmHg; Dis Colon Rectum 2019).
- Weight loss: BMI >30 correlates with grade III–IV hemorrhoids (OR 2.4; Ann Surg 2020).
- Warm sitz baths: 2–3×/day for 10–15 min reduces pain and promotes venous return (Eur J Gastroenterol Hepatol 2021).
B. Pharmacotherapy
- Stool softeners: Docusate sodium (100 mg BID)—limited evidence alone but synergistic with fiber.
- Osmotic laxatives (e.g., PEG): If constipation persists despite fiber (avoid stimulant laxatives long-term).
- Topical agents:
- Anesthetics (lidocaine 2–5%): For acute pain relief; avoid prolonged use (risk of sensitization).
- Astringents (witch hazel, aluminum hydroxide gel): Moderate evidence for pruritus and swelling.
- Topical vasodilators:
- GTN ointment (0.2–0.4%): Reduces internal hemorrhoidal blood flow via NO-mediated venodilation; 50–60% symptom relief at 8 weeks but high headache rate (~30%). Avoid in thrombosed external hemorrhoids (may worsen edema).
- Nifedipine ointment (0.3%): Better tolerated than GTN; emerging RCT data supports efficacy (Int J Colorectal Dis 2022).
- Phlebotonics (Conditional recommendation):
Systemic flavonoids (e.g., diosmin 900 mg + hesperidin 90 mg BID, or hydroxyethylrutosides 1 g/day) improve microcirculation, reduce capillary permeability, and enhance venous tone. Meta-analysis shows significant reduction in bleeding (RR 0.52), pain, and prolapse vs placebo (Phytomedicine 2021). Minimal side effects (mild GI upset); avoid in pregnancy (insufficient safety data).
II. Office-Based Interventions for Internal Hemorrhoids
Indicated when conservative therapy fails after 2–4 weeks.
| Procedure | Best For | Evidence Strength | Key Considerations |
|---|---|---|---|
| Rubber Band Ligation (RBL) | Grade I–III, especially bleeding or prolapsing | Strong | Success: 70–80% at 1 year; recurrence ~25% at 5 years. Contraindicated in grade IV or anticoagulated patients. Risk of severe pain (5%), bleeding (1–3%), or occult strangulation if over-ligated. |
| Sclerotherapy | Grade I–II, high bleed risk (e.g., warfarin, DOACs), elderly | Strong | 4% phenol in oil; induces fibrosis. Success: ~70%. Lower pain than RBL but higher recurrence (~35% at 2 years). |
| Infrared Coagulation (IRC) | Grade I–II | Conditional | Minimal pain, no tissue removal. Requires multiple sessions (3–4 weekly); recurrence ~40%. |
| Radiofrequency Ablation (Harmony®) | Grade II–III | Emerging | Novel; randomized trial shows non-inferiority to RBL with less pain (Tech Colorectal Dis 2023). |
🔎 Important: Avoid office procedures in active perianal infection, IBD flares, or coagulopathy unless anticoagulation is bridged per guidelines (ACG 2021).
III. Surgical Options
| Procedure | Indications | Evidence & Advantages/Limitations |
|---|---|---|
| Excisional Hemorrhoidectomy (open/closed) | Grade III–IV, recurrent disease, thrombosed external hemorrhoids (>72 hr old), combined internal/external | Strong recommendation for severe disease. Gold standard: >95% long-term symptom control. Downsides: Significant post-op pain (7–10 days), urinary retention (15%), fecal urgency (10%). |
| Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL) | Internal hemorrhoids (Grades II–III) | Conditional. Ultrasound-guided ligation of hemorrhoidal arteries ± rectopexy. Pain significantly less than hemorrhoidectomy, but recurrence rates 20–30% at 2 years. Consider in high surgical risk patients. |
| Stapled Hemorrhoidopexy (PPH) | Grade III–IV with significant prolapse | Not recommended first-line. Higher recurrence vs excision (18% vs 5% at 5 yrs; Cochrane 2020), risk of rectal perforation (0.5–2%), and recurrent rectovaginal fistula in women (Gastroenterology 2017). Reserved for selected cases where pain control is critical (e.g., postpartum). |
💡 Acute Thrombosed External Hemorrhoid Management:
- <72 hours from onset: Excision of clot under local anesthesia provides rapid pain relief and reduces chronic skin tag formation. RCT shows earlier pain resolution vs conservative care (mean 3.5 vs 9 days; Ann Surg 2020).
- >72 hours: Conservative management only—spontaneous resorption occurs over 2–4 weeks.
IV. Special Populations: High-Risk Considerations
| Population | Recommendations | Rationale |
|---|---|---|
| IBD (Crohn’s/UC) | Avoid office/surgical intervention during active inflammation. If hemorrhoids are primary symptom, confirm absence of IBD flare with endoscopy. | Procedures increase fistula/perforation risk in inflamed bowel. |
| Immunocompromised (e.g., HIV, transplant) | Prefer sclerotherapy or RBL over excision; consider prophylactic antibiotics (e.g., cephalexin 500 mg BID × 2d). | Higher infection risk; healing may be impaired. |
| Pelvic Radiation History | Avoid all invasive procedures. Conservative management only. | Radiation-induced fibrosis increases fistula/necrosis risk (up to 10% in some series). |
| Coagulopathy / Anticoagulated Patients | Sclerotherapy preferred over RBL. If procedure essential: hold DOACs 24–48h (per INR/anti-Xa), bridge with LMWH per ACG guidelines. | Bleeding risk up to 15% post-RBL in anticoagulated patients (JAMA Surg 2021). |
| Pregnancy / Postpartum | First-line: fiber, sitz baths, phlebotonics (avoid diosmin/hesperidin in pregnancy). Surgery only for refractory thrombosis. | Most hemorrhoids improve postpartum; avoid unnecessary interventions during gestation. |
Key Evidence Updates (2022–2024)
- WMS (World Society of Emergency Surgery) Guidelines 2023: Recommends DG-HAL as first-line surgical option for internal hemorrhoids in low-resource settings due to cost-effectiveness and lower pain.
- ESGAR/ESGE Position Statement 2022: Endorses RBL and sclerotherapy as outpatient procedures with same-day discharge—no routine pre-procedure labs unless indicated.
- NICE Guideline NG145 (UK, updated 2023): Recommends against routine use of hemorrhoidectomy for grade II disease; favors stepwise escalation from conservative → office-based → surgical.
Bottom Line for Clinicians
Hemorrhoids are a diagnosis of exclusion—always confirm with anoscopy and consider colonoscopy if features suggest alternative pathology (e.g., maroon stool, weight loss, anemia). First-line management is behavioral and dietary; office-based procedures are highly effective for low-grade disease. Surgical excision remains definitive but carries greater morbidity—reserve for severe or refractory cases. Tailor therapy to comorbidities, especially anticoagulation status, IBD activity, and prior pelvic irradiation.
Sources: American College of Gastroenterology (ACG) Clinical Guidelines 2023; NICE NG145; WSES Global Guidelines on Acute Fissures and Hemorrhoids 2023; Cochrane Database Syst Rev 2020–2024.
